AVTR vs. RVMD: Avantor vs. Revolution Medicines Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Revolution Medicines (RVMD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Revolution Medicines (RVMD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while RVMD is classified in Biotechnology.

Company profile comparison for Avantor (AVTR) and Revolution Medicines (RVMD)
Profile Item	AVTR	RVMD
Name	Avantor, Inc.	Revolution Medicines, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	10.48 billion USD	41.59 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	May 17, 2019	February 13, 2020
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

RVMD

GSPC

Avantor (AVTR) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Revolution Medicines (RVMD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Revolution Medicines (RVMD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
Total Return (1Y)	36.41%	224.80%
Total Return (3Y, Annualized)	-5.02%	114.71%
Total Return (5Y, Annualized)	-16.62%	43.47%

Risk Profile

Drawdown History

AVTR

RVMD

GSPC

Avantor (AVTR) vs. Revolution Medicines (RVMD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Revolution Medicines (RVMD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
Volatility (1Y, Annualized)	43.39%	68.29%
Beta (5Y)	0.94	1.42
Max Drawdown (5Y)	-82.42%	-55.71%
Avg. Volume (3M)	8.56M	2.06M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and RVMD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
Sharpe Ratio (1Y)	0.74	3.23
Sortino Ratio (1Y)	1.17	6.92

Profitability

ROE (TTM)

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Avantor (AVTR) reports 5.91%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-93.56%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
RVMD: -93.56%
Min: -167.77%

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Avantor (AVTR) at 5.08% retains a top-quartile share of revenue as profit, ahead of Revolution Medicines (RVMD) at 0.00%, which keeps about the industry-typical share.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
RVMD: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Avantor (AVTR) reports 8.19%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-188.88%

Max: 83.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
RVMD: -188.88%
Min: -207.40%

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
ROE (TTM)	5.91%	-93.56%
ROA (TTM)	2.83%	-32.13%
Net Margin (TTM)	5.08%	0.00%
Operating Margin (TTM)	8.19%	-188.88%
Gross Margin (TTM)	31.59%	0.00%

Growth

Revenue Growth

Only one side can be read here: Avantor (AVTR) reports revenue growth of -3.41%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Avantor (AVTR) reports EPS growth of -175.00%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
Revenue Growth (YoY)	-3.41%	--
Revenue Growth (3Y CAGR)	-4.46%	--
EPS Growth (YoY)	-175.00%	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Revolution Medicines (RVMD) at 8.36 keeps current ratio within its industry’s typical mid-range, while Avantor (AVTR) at 1.89 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AVTR.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.36

Max: 25.13
Q3: 12.13
RVMD: 8.36
Median: 5.52
Q1: 2.47
Min: 0.10

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Avantor (AVTR) at 0.63 and Revolution Medicines (RVMD) at 0.50 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.50

Max: 1.42
Q3: 0.65
RVMD: 0.50
Median: 0.15
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
Current Ratio (MRQ)	1.89	8.36
Debt / Equity (MRQ)	0.63	0.50
Net Debt / EBITDA	3.40	--

Dividends

Dividend Yield (TTM)

Neither Avantor (AVTR) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Avantor (AVTR) nor Revolution Medicines (RVMD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RVMD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Avantor (AVTR) trades at 30.94 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
RVMD: --

Avantor (AVTR) vs. Revolution Medicines (RVMD): RVMD does not report P/E ratio, so it has no value marker; AVTR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Revolution Medicines (RVMD) at 210.51 prices above its industry range — a wide gap in sales valuation between them.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

210.51

RVMD: 210.51
Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Avantor (AVTR) at 1.80 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

RVMD

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.31

RVMD: 17.31
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Revolution Medicines (RVMD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Revolution Medicines (RVMD)
Metric	AVTR	RVMD
P/E Ratio (TTM)	30.94	--
P/S Ratio (TTM)	1.58	210.51
P/B Ratio (MRQ)	1.80	17.31
Free Cash Flow Yield (TTM)	4.21%	-2.13%